|Bid||20.63 x 800|
|Ask||52.00 x 800|
|Day's range||40.99 - 41.56|
|52-week range||40.99 - 58.00|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||18.87|
|Earnings date||01 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||54.56|
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
HILDEN, Germany & GERMANTOWN, Md., September 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses. The new assays for the identification and quantification of the Epstein-Barr virus (EBV) and the human herpesvirus 6 (HHV-6) have received CE-IVD certification for the European Union and other countries that accept this marking.